

A multidisciplinary approach to treat hepatitis C infection in people who inject drugs

Francina Fonseca (1,2,3), Montserrat García-Retortillo (2,3,4), Elena González-Colominas (3,5), Núria Cañete (2,3,4), Daniel Roca (6), Ana Viu (2,4), Rosa Fernández (2,4), Judit Romero (2,4), Esther Garrido (2,4), Gemma Díaz (4), Gabriel Vallecillo (1,2), Joan Vidal (7), Teresa Broquetas (2,4), Marc Puigvehí (2,3,4), José Antonio Carrión (3,4), Susanna Coll (2,3,4), Nuria Carballo (5), Laura Río (5), Santiago Grau (3,5), Xavier Bessa (2,3,4), Marta Torrens (1,2,3)

¹ Institut de Neuropsiquiatria i Addiccions (INAD), Barcelona, Spain. ² Hospital del Mar Medical Research Institute-IMIM, Barcelona, Spain.

³ Universitat Autònoma Barcelona-UAB, School of Medicine, Barcelona, Spain. ⁴ Liver Section, Gastroenterology Service, Hospital del Mar, Barcelona, Spain.

⁵ Pharmacy Service, Hospital del Mar, Barcelona, Spain. ⁶ CAS Baluard, Barcelona, Spain. ⁷ CECAS, Barcelona, Spain.

Contact: mffonseca@psmar.cat

Background

Hepatitis C (HCV) treatment in people who inject drugs (PWID) supposes a challenge due to poor access to treatment, with lower rates of sustained virological response (SVR, defined as undetectable HCV viral load 12 weeks after end of antiviral treatment)¹. The prevalence of severe HCV-related liver disease among PWID is increasing, but treatment uptake remains low. Direct-acting antiviral (DAA) therapy for HCV infection allows to treat and cure HCV in short time and with well toleration.²

A multidisciplinary approach has been created (PAM-ADIC-C) to improve screening, diagnosis, assessment, and treatment in HCV patients under addiction treatment.

Aim

The aim is to describe the PAM-ADIC-C ongoing protocol and to present the results on adherence and SVR.

Methods

Since 2019 a network of centers/professionals treating addicted patients in our catchment area has been developed. The program is based in: a) point-of-care testing and fast referral from the drug-addiction center; b) accompaniment to visits by social educators; c) reduction in the number of visits; d) pharmacy externalization and on-site treatment delivery; e) coordination and evaluation of program results (Figure 1).

We have obtained socio-demographical data, hepatitis C infection data, substance use, comorbidity. Hepatic fibrosis was evaluated with portable transient elastography. Adherence rate has been calculated in patients that completed the treatment.

Results

A total of 119 patients have been referred from the centers of the catchment area, and a total of 95 have been assessed (80%) (Figure 2). Patients assessed were male (79%), mean age: 45±9 years; six had received previous treatment and 26% presented advanced liver fibrosis (F3-F4) (Figure 3). The 87% of subjects were in OAT (mainly methadone). The 54% presented a comorbid diagnosis (no substance use related) (Figure 4). A total of 83 patients completed the treatment, and 54 have completed 12 weeks after end-of-treatment; mean adherence of 97%. SVR has been achieved in 52/54 (Figures 5).

Figure 2. Patients referred and visited. Green column are patients referred and blue column are patients visited at least once.




Figure 3. Basal characteristics of the 95 patients admitted to treatment.

	N= 95
Males	75 (79%)
Age	45 ± 9 (26-66)
Previous treatment	6 (6,3%)
Basal RNA (UI/ml)	3.494.615 ± 77.48.905 (61-64.029.000)
Genotype	
1a	37 (39%)
1b	8 (8,4%)
3a	24 (25,3%)
4a	11 (11,6%)
4d	5 (5,3%)
Basal Transient elastography	10,62 ± 12,53 (3,5 – 74,4)
Advanced fibrosis (F3-F4)	25 (26%)

Conclusion

A multidisciplinary approach and the co-location of care for HCV infection and addiction treatment in PWID is a strategy to achieve better access and more efficacy of HCV treatment in this population.

References

1. Grebely J, Bruneau J, Lazarus JV, et al. Research priorities to achieve universal access to hepatitis C prevention, management and direct-acting antiviral treatment among people who inject drugs. Int J Drug Policy. 2017, 47:51-60. doi: 10.1016/j.drugpo.2017.05.019.
2. Grebely J, Robaey G, Bruggmann P, et al. International Network for Hepatitis in Substance Users. Recommendations for the management of hepatitis C virus infection among people who inject drugs. Int J Drug Policy. 2015, 26:1028-38. doi: 10.1016/j.drugpo.2015.07.005.

Supported by: Instituto de Salud Carlos III-FEDER-Red de Trastornos Adictivos UE-FEDER 2016 (RD16/0017/0010); AGAUR-Suport Grups de Recerca (2017 SGR530).

Figure 1. Multidisciplinary PAM-ADIC-C protocol. Pre-treatment visits are done in the Drug Addiction Center. Basal and Follow-up visits are performed in the General Hospital.

Pre-Treatment (Addiction Center)
<ul style="list-style-type: none">- Hepatitis C diagnosis infection in the center (Physician/Psychiatrist)- Substance use assessment (Physician/Psychiatrist)- Psychiatric comorbidity assessment (Psychiatrist)- Medication adherence evaluation (Drug Addiction team)
Basal visit (Social Educator accompanies the patient)
<ul style="list-style-type: none">- Blood Test (Nurse)- Portable transient elastography (Liver Specialist)- Drug Interactions evaluation (Pharmacist) <p>Antiviral treatment is indicated</p> <p>Treatment is given to Social Educators to be administered in the Drug Addiction Center</p>
Follow up visits: Social Educator accompanies the patient
<ul style="list-style-type: none">- End of treatment visit (8 or 12 weeks)- Follow up visit: to determine SVR (3 months SVR12)- Reinfection control: (every 6 months)

Figure 4. HIV, other drug, and psychiatric comorbidity of the 95 patients admitted to treatment.

	N= 95
HIV	38 (40%)
Main Drug	
Heroin	90 (95%)
Cocain	2 (2%)
Alcohol	3 (3%)
Opioid Substitution Treatment	83 (87%)
Dual Diagnosis	51 (54%)
Affective disorders	12 (13%)
Psychosis	10 (11%)
Anxiety	4 (4%)
Personality Disorders	28 (30%)

Figure 5. Outcomes for the 95 patients admitted to treatment.

	N= 95
Treatment situation	
Treatment completed (re-infection follow-up)	54 (57%)
Completed treatment (before SVR12)	29 (31%)
In treatment	5 (5%)
Basal RNA suppressed	1 (1%)
Completing proves	1 (1%)
Treatment	
Glecaprevir/Pibrentasvir	45 (47%)
Sofosbuvir/velpastavir	49 (51%)
Ledipasvir/sofosbuvir	1 (1%)
SVR	52/54
Adherence to medication	97% (50-100)
Stoped treatment due to adverse events	0
People who not completed treatment	5 (5%)
Reinfections	1/54